HCPCS Level IIdrugActive
J3403
Revakinagene, per implant
BETOS: O1E
Effective: 2025-10-01
Referenced in 1 policies
Description
Revakinagene taroretcel-lwey, per implant
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Encelto
Manufacturer
Neurotech Pharmaceuticals, Inc.
HCPCS Dosage
PER IMPLANT
Billing Units
1.0000
1
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.